Migraine

Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.

Your daily dose of the clinical news you may have missed.

Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.

The phase 4 APPRAISE trial found greater efficacy with erenumab after failure with 1 or 2 other preventives vs ongoing treatment with the nonspecific oral agents.

Your daily dose of the clinical news you may have missed.

Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.

Your daily dose of the clinical news you may have missed.

Which medications are most effective for acute migraine management? A recent study assessed which ones appeared to work best based on reported patient experience.

Common triggers, such as stress, travel, and disrupted routines, can impact patients with migraine this holiday season. Practical strategies and short-term preventive measures to help, here.

Which antihypertensive therapy options are most and least effective for patients with migraine? Get details, here.

Get details on which migraine treatments are the better option for women who are breastfeeding, and on ones to advise them to avoid.

An overview of safe treatment options for migraine attacks that may occur during pregnancy for primary care clinicians, here.

The device from Nexalin Technology outperformed placebo on key measures of pain relief, sleep quality, anxiety, and quality of life.

An overview of oral preventive medication options for migraine for primary care clinicians, here.

A daily dose of clinical news on Patient Care you may have missed.

The oral gepant reduced monthly migraine days as well as mean monthly use of migraine rescue medication.

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?

An overview of common headache conditions and treatments for primary care clinicians, here.

Menstrual migraine is often described as more disabling than non-menstrual migraine. Get an overview and test your knowledge, here.

Your daily dose of clinical news you may have missed.

The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.

The role of the trigeminal nerve and its connection to the brainstem has led to a greater understanding of where migraine pain originates. Expert explains, here.

The oral calcitonin gene-related peptide receptor antagonist is now indicated for prevention in both episodic and chronic migraine.

To be marketed as Rizafilm, the product is a disintegrating film formulation of the 5-HT-1 receptor antagonist and proven bioequivalent to Merck's Maxalt-MLT.

Zavegepant, the first FDA-approved intranasal CGRP receptor antagonist, could be available in pharmacies by July 2023.

The prescription remote electrical neuromodulation device is now cleared for both acute and preventive treatment of migraine in those aged ≥12 years, according to Theranica.

Pain relief from the intranasally-delivered calcitonin gene-related peptide antagonist began as soon as 15 minutes post-dose and for some patients lasted up to 48 hours.

Your daily dose of clinical news you may have missed.